Latest Simcere Pharmaceutical Group (SCR) Headlines
12.3% Return Seen to Date on SmarTrend Simcere Pharmaceutical Group Call (SCR)
Comtex SmarTrend(R) - Thu Mar 13, 5:31PM CDT
SmarTrend identified an Uptrend for Simcere Pharmaceutical Group (NYSE:SCR) on September 28th, 2012 at $8.55. In approximately 18 months, Simcere Pharmaceutical Group has returned 12.35% as of today's recent price of $9.60.
Simcere Pharmaceutical Group Up 12.3% Since SmarTrend Uptrend Call (SCR)
Comtex SmarTrend(R) - Thu Mar 06, 11:18AM CST
SmarTrend identified an Uptrend for Simcere Pharmaceutical Group (NYSE:SCR) on September 28th, 2012 at $8.55. In approximately 17 months, Simcere Pharmaceutical Group has returned 12.35% as of today's recent price of $9.60.
Simcere Pharmaceutical Group Shares Up 12.3% Since SmarTrend's Buy Recommendation (SCR)
Comtex SmarTrend(R) - Thu Feb 27, 10:02AM CST
SmarTrend identified an Uptrend for Simcere Pharmaceutical Group (NYSE:SCR) on September 28th, 2012 at $8.55. In approximately 17 months, Simcere Pharmaceutical Group has returned 12.35% as of today's recent price of $9.60.
Uptrend Call Working As Simcere Pharmaceutical Group Stock Rises 12.3% (SCR)
Comtex SmarTrend(R) - Wed Feb 12, 9:51AM CST
SmarTrend identified an Uptrend for Simcere Pharmaceutical Group (NYSE:SCR) on September 28th, 2012 at $8.55. In approximately 17 months, Simcere Pharmaceutical Group has returned 12.35% as of today's recent price of $9.60.
Shares of SCR Up 12.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 05, 9:28AM CST
SmarTrend identified an Uptrend for Simcere Pharmaceutical Group (NYSE:SCR) on September 28th, 2012 at $8.55. In approximately 17 months, Simcere Pharmaceutical Group has returned 12.35% as of today's recent price of $9.60.
ManpowerGroup Reports 4th Quarter and Full Year 2013 Results
PR Newswire - Thu Jan 30, 6:30AM CST
ManpowerGroup (NYSE: MAN) today reported net earnings of $1.25 per diluted share for the three months ended December 31, 2013 compared to 68 cents per diluted share in the prior period. The net earnings in the quarter were $101.2 million compared to $53.3 million a year earlier. Revenues for the fourth quarter totaled $5.3 billion, an increase of 1 percent from the year earlier period in U.S. dollars and constant currency.
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Simcere Pharmaceutical Group Announces Completion of Merger
PR Newswire - Mon Dec 23, 3:27PM CST
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the completion of the merger contemplated by the previously announced Agreement and Plan of Merger dated August 28, 2013 (the "Merger Agreement") among the Company, Simcere Holding Limited ("Parent") and Simcere Acquisition Limited ("Merger Sub"). As a result of the merger, the Company became a wholly owned subsidiary of Parent.
Simcere Pharmaceutical Group Announces Shareholders' Approval of the Merger Agreement
PR Newswire - Thu Dec 19, 4:00AM CST
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that at an extraordinary general meeting held today, the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced Agreement and Plan of Merger dated August 28, 2013 (the "Merger Agreement") among the Company, Simcere Holding Limited ("Parent") and Simcere Acquisition Limited ("Merger Sub"), pursuant to which Merger Sub will be merged with and into the Company with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), and any and all transactions contemplated by the Merger Agreement, including the Merger.
Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
PR Newswire - Fri Nov 22, 4:00AM CST
Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that the annual general meeting of shareholders (the "Meeting") will be held on Thursday, December 19, 2013 at 9 a.m. Beijing time. The meeting will be held at No.699-18, Xuanwu Avenue, Xuanwu District, Nanjing, People's Republic of China.
Simcere Pharmaceutical Group Announces Extraordinary General Meeting of Shareholders
PR Newswire - Tue Nov 19, 11:15AM CST
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, announced today that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held on December 19, 2013 at 10:00 a.m. (Beijing Time). The meeting will be held at No. 699-18, Xuan Wu Avenue, Xuan Wu District, Nanjing, Jiangsu Province 210042, People's Republic of China, to consider and vote on, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger (the "Merger Agreement") dated August 28, 2013 among the Company, Simcere Holding Limited and Simcere Acquisition Limited ("Merger Sub"), the plan of merger (the "Plan of Merger") and the transactions contemplated thereby.
Simcere Reports a Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 18, 11:57AM CST
Simcere Pharmaceutical Group reported a third quarter 2013 loss of 2 cents per American Depositary Share (ADS) which compared unfavorably to the Zacks Consensus Estimate of an earnings per share of 6 cents per ADS.
Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2013 Results
PR Newswire - Thu Nov 14, 4:25AM CST
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended September 30, 2013.
Altravax Announces the Appointment of Dr. Sean X. Du as Chief Operating Officer
Business Wire - Fri Nov 01, 10:16AM CDT
Altravax, Inc. today announced the appointment of Dr. Sean X. Du to the role of Chief Operating Officer. He joins Altravax from Simcere Pharmaceuticals Group (NYSE:SCR) where he was Executive Director, Institute of Vaccine Research. Dr. Du established Simcere's R&D capabilities for new generation vaccines and was also involved in the evaluation of vaccine-related collaborations and M&A opportunities. He led preclinical development of both a therapeutic hepatitis B vaccine and Vero-cell-based rabies vaccine, with the later program achieving a clinical filing to the Chinese SFDA. Prior to joining Simcere, he was Senior Scientist and Project Leader at Maxygen, Inc. focusing on vaccines for infectious diseases, and subsequently a co-founder of Altravax. Dr. Du holds a B.S. degree from Shandong University, an M. S. degree from the Chinese Academy of Sciences (Beijing), and a Ph.D. from the University of Delaware. He also received postdoctoral training at Columbia University College of Physicians and Surgeons before joining Maxygen in 2001.
Simcere Pharmaceutical Group to Announce Third Quarter 2013 Financial Results on Thursday, November 14, 2013
PR Newswire - Fri Nov 01, 5:00AM CDT
Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2013 on Thursday, November 14, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, November 14, at 9 p.m. Beijing / Hong Kong time).
Simcere Pharmaceutical Group names Dr Zang Jingwu as chief scientific officer of its R&D
M2 - Tue Oct 15, 6:04AM CDT
Pharmaceutical company Simcere Pharmaceutical Group (NYSE:SCR) revealed on Tuesday the election of Dr Zang Jingwu as its chief scientific officer of R&D effective 8 October 2013.
Simcere Pharmaceutical Group Announces Appointment of Chief Scientific Officer
PR Newswire - Tue Oct 15, 5:34AM CDT
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the appointment of Dr. Zang Jingwu as Chief Scientific Officer of the Company, effective October 8, 2013.
OTC Signal Daily Stock Watch - Simcere Pharmaceutical Group (NYSE: SCR)
WorldStockWire - Wed Sep 04, 1:45AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
12.3% Return Seen to Date on SmarTrend Simcere Pharmaceutical Group Call (SCR)
Comtex SmarTrend(R) - Thu Mar 13, 5:31PM CDT
SmarTrend identified an Uptrend for Simcere Pharmaceutical Group (NYSE:SCR) on September 28th, 2012 at $8.55. In approximately 18 months, Simcere Pharmaceutical Group has returned 12.35% as of today's recent price of $9.60.
Simcere Pharmaceutical Group Up 12.3% Since SmarTrend Uptrend Call (SCR)
Comtex SmarTrend(R) - Thu Mar 06, 11:18AM CST
SmarTrend identified an Uptrend for Simcere Pharmaceutical Group (NYSE:SCR) on September 28th, 2012 at $8.55. In approximately 17 months, Simcere Pharmaceutical Group has returned 12.35% as of today's recent price of $9.60.
Simcere Pharmaceutical Group Shares Up 12.3% Since SmarTrend's Buy Recommendation (SCR)
Comtex SmarTrend(R) - Thu Feb 27, 10:02AM CST
SmarTrend identified an Uptrend for Simcere Pharmaceutical Group (NYSE:SCR) on September 28th, 2012 at $8.55. In approximately 17 months, Simcere Pharmaceutical Group has returned 12.35% as of today's recent price of $9.60.
Uptrend Call Working As Simcere Pharmaceutical Group Stock Rises 12.3% (SCR)
Comtex SmarTrend(R) - Wed Feb 12, 9:51AM CST
SmarTrend identified an Uptrend for Simcere Pharmaceutical Group (NYSE:SCR) on September 28th, 2012 at $8.55. In approximately 17 months, Simcere Pharmaceutical Group has returned 12.35% as of today's recent price of $9.60.
Shares of SCR Up 12.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 05, 9:28AM CST
SmarTrend identified an Uptrend for Simcere Pharmaceutical Group (NYSE:SCR) on September 28th, 2012 at $8.55. In approximately 17 months, Simcere Pharmaceutical Group has returned 12.35% as of today's recent price of $9.60.
ManpowerGroup Reports 4th Quarter and Full Year 2013 Results
PR Newswire - Thu Jan 30, 6:30AM CST
ManpowerGroup (NYSE: MAN) today reported net earnings of $1.25 per diluted share for the three months ended December 31, 2013 compared to 68 cents per diluted share in the prior period. The net earnings in the quarter were $101.2 million compared to $53.3 million a year earlier. Revenues for the fourth quarter totaled $5.3 billion, an increase of 1 percent from the year earlier period in U.S. dollars and constant currency.
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Simcere Pharmaceutical Group Announces Completion of Merger
PR Newswire - Mon Dec 23, 3:27PM CST
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the completion of the merger contemplated by the previously announced Agreement and Plan of Merger dated August 28, 2013 (the "Merger Agreement") among the Company, Simcere Holding Limited ("Parent") and Simcere Acquisition Limited ("Merger Sub"). As a result of the merger, the Company became a wholly owned subsidiary of Parent.
Simcere Pharmaceutical Group Announces Shareholders' Approval of the Merger Agreement
PR Newswire - Thu Dec 19, 4:00AM CST
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that at an extraordinary general meeting held today, the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced Agreement and Plan of Merger dated August 28, 2013 (the "Merger Agreement") among the Company, Simcere Holding Limited ("Parent") and Simcere Acquisition Limited ("Merger Sub"), pursuant to which Merger Sub will be merged with and into the Company with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), and any and all transactions contemplated by the Merger Agreement, including the Merger.
Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
PR Newswire - Fri Nov 22, 4:00AM CST
Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that the annual general meeting of shareholders (the "Meeting") will be held on Thursday, December 19, 2013 at 9 a.m. Beijing time. The meeting will be held at No.699-18, Xuanwu Avenue, Xuanwu District, Nanjing, People's Republic of China.
Simcere Pharmaceutical Group Announces Extraordinary General Meeting of Shareholders
PR Newswire - Tue Nov 19, 11:15AM CST
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, announced today that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held on December 19, 2013 at 10:00 a.m. (Beijing Time). The meeting will be held at No. 699-18, Xuan Wu Avenue, Xuan Wu District, Nanjing, Jiangsu Province 210042, People's Republic of China, to consider and vote on, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger (the "Merger Agreement") dated August 28, 2013 among the Company, Simcere Holding Limited and Simcere Acquisition Limited ("Merger Sub"), the plan of merger (the "Plan of Merger") and the transactions contemplated thereby.
Simcere Reports a Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 18, 11:57AM CST
Simcere Pharmaceutical Group reported a third quarter 2013 loss of 2 cents per American Depositary Share (ADS) which compared unfavorably to the Zacks Consensus Estimate of an earnings per share of 6 cents per ADS.
Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2013 Results
PR Newswire - Thu Nov 14, 4:25AM CST
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended September 30, 2013.
Altravax Announces the Appointment of Dr. Sean X. Du as Chief Operating Officer
Business Wire - Fri Nov 01, 10:16AM CDT
Altravax, Inc. today announced the appointment of Dr. Sean X. Du to the role of Chief Operating Officer. He joins Altravax from Simcere Pharmaceuticals Group (NYSE:SCR) where he was Executive Director, Institute of Vaccine Research. Dr. Du established Simcere's R&D capabilities for new generation vaccines and was also involved in the evaluation of vaccine-related collaborations and M&A opportunities. He led preclinical development of both a therapeutic hepatitis B vaccine and Vero-cell-based rabies vaccine, with the later program achieving a clinical filing to the Chinese SFDA. Prior to joining Simcere, he was Senior Scientist and Project Leader at Maxygen, Inc. focusing on vaccines for infectious diseases, and subsequently a co-founder of Altravax. Dr. Du holds a B.S. degree from Shandong University, an M. S. degree from the Chinese Academy of Sciences (Beijing), and a Ph.D. from the University of Delaware. He also received postdoctoral training at Columbia University College of Physicians and Surgeons before joining Maxygen in 2001.
Simcere Pharmaceutical Group to Announce Third Quarter 2013 Financial Results on Thursday, November 14, 2013
PR Newswire - Fri Nov 01, 5:00AM CDT
Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2013 on Thursday, November 14, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, November 14, at 9 p.m. Beijing / Hong Kong time).
Simcere Pharmaceutical Group names Dr Zang Jingwu as chief scientific officer of its R&D
M2 - Tue Oct 15, 6:04AM CDT
Pharmaceutical company Simcere Pharmaceutical Group (NYSE:SCR) revealed on Tuesday the election of Dr Zang Jingwu as its chief scientific officer of R&D effective 8 October 2013.
Simcere Pharmaceutical Group Announces Appointment of Chief Scientific Officer
PR Newswire - Tue Oct 15, 5:34AM CDT
Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the appointment of Dr. Zang Jingwu as Chief Scientific Officer of the Company, effective October 8, 2013.
OTC Signal Daily Stock Watch - Simcere Pharmaceutical Group (NYSE: SCR)
WorldStockWire - Wed Sep 04, 1:45AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
